Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells

International Journal of Cancer

Volumn 115, Issue 1, 2005, Pages 65-73

  Eskandarpour, Malihe ^a   Kiaii, Shahryar ^a   Zhu, Chaoyong ^a   Castro, Juan ^a   Sakko, Andrew J ^a   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Melanoma; Ras; RNAi; Signal transduction

Indexed keywords

ADENINE; CYCLIN D1; CYTOSINE; GLUTAMIC ACID; GLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; VALINE;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BRAF GENE; CARCINOGENESIS; CODON; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; NRAS GENE; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CODON; COLORING AGENTS; CYCLIN D1; DOWN-REGULATION; ETHIDIUM; GENES, RAS; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MELANOMA; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PLASMIDS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 17644383337     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20873     Document Type: Article

References (43)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
2. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001;171:1-10.
3. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000;57:1613-36.
4. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
5. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference-new hope for a highly specific cancer treatment? Cancer Cell 2002;2:167-8.
6. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
7. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993;62:851-91.
8. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-8.
9. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen O, O'Hagan R, Pantginis I, Zhou H, Horner IW 2nd, Cardon-Cardo C, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-72.
10. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003;95:790-8.
11. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002;8:3468-74.
12. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102:285-90.
13. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998;111:757-61.
14. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DI, Schrier PI. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883-93.
15. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-74.
16. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54.
17. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62:7335-42.
18. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA. Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation. Oncogene 2002;21:1527-38.
19. Downward J. Signal transduction. New exchange, new target. Nature 1998;396:416-7.
20. Feig LA, Buchsbaum RJ. Cell signaling: life or death decisions of ras proteins. Curr Biol 2002;12:R259-61.
21. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 2002;192:125-30.
22. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- und 22-nucleotide RNAs. Genes Dev 2001;15:188-200.
23. Sharp PA. RNA interference - 2001. Genes Dev 2001;15:485-90.
24. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
25. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 2001;3:950-7.
26. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22:355-8.
27. Joneson T, Bar-Sagi D. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol 1999;19:5892-901.
28. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002;1:599-606.
29. Demunter A, Stas M, Degreef H, De Wolf-Peelers C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001;117:1483-9.
30. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-67.
31. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7.
32. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62.
33. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7.
34. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 2003;22:5694-701.
35. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
36. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A. Taira K, Kawakami Y. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004;23:6031-9.
37. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997;7:63-70.
38. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed IC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
39. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
40. Yang E, Zha J, Jockei J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
41. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
42. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
43. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 1993;90:8319-23.